MaxCyte, Inc. (AIM: MXCT)

Market Cap	310.16M
Revenue (ttm)	35.95M
Net Income (ttm)	-28.03M
Shares Out	105.14M
EPS (ttm)	-0.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,244
Open	300.00
Previous Close	295.00
Day's Range	290.25 - 300.00
52-Week Range	180.00 - 430.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 20, 2024

About MaxCyte

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engin...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1998
• Employees: 143
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: MXCT

Financial Performance

In 2023, MaxCyte's revenue was $41.29 million, a decrease of -6.72% compared to the previous year's $44.26 million. Losses were -$37.92 million, 60.9% more than in 2022.

Financial numbers in USD